Cytodyn Inc Investor Call Transcript
Thank you, Mike, and thank you, everyone, for being on the call today. Before I start the call, I want to thank so many of you shareholders for really supporting leronlimab and going out of your way, trying to bring awareness about our product to politicians and other health professionals.
CytoDyn just announced a few minutes ago that the company has been granted a meeting with MHRA to discuss fast track approval in a teleconference on September 9, which is just seven days from today. We have been having a very positive dialogue with MHRA, and I will explain this right now in great detail.
On August 14, CytoDyn asked MHRA UK regulatory agency to consider granting fast-track approval for leronlimab based on CD10 results and our top line report was sent to them along with emergency IND patients and other data. On August 24, just 10 days later, MHRA responded to us by indicating that we have reviewed your request and are sending your request to senior management team in licensing division for further inputs.
We aim to have a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
